Vanguard Group Inc lifted its position in Calyxt Inc (NASDAQ:CLXT) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 377,640 shares of the company’s stock after purchasing an additional 7,246 shares during the period. Vanguard Group Inc owned about 1.16% of Calyxt worth $5,766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently made changes to their positions in CLXT. California Public Employees Retirement System purchased a new position in Calyxt during the second quarter valued at $187,000. Essex Investment Management Co. LLC bought a new position in Calyxt during the third quarter valued at $309,000. Millennium Management LLC bought a new position in Calyxt during the second quarter valued at $582,000. Blair William & Co. IL lifted its position in Calyxt by 8.8% during the third quarter. Blair William & Co. IL now owns 52,681 shares of the company’s stock valued at $804,000 after purchasing an additional 4,280 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Calyxt by 12.1% during the second quarter. Northern Trust Corp now owns 63,779 shares of the company’s stock valued at $1,191,000 after purchasing an additional 6,903 shares during the last quarter. 28.60% of the stock is owned by hedge funds and other institutional investors.
NASDAQ CLXT traded up $0.22 during trading on Monday, reaching $13.23. 5,673 shares of the company’s stock traded hands, compared to its average volume of 48,064. The company has a debt-to-equity ratio of 0.17, a quick ratio of 15.01 and a current ratio of 15.01. The company has a market capitalization of $423.77 million, a price-to-earnings ratio of -11.81 and a beta of 2.70. Calyxt Inc has a 12-month low of $8.83 and a 12-month high of $23.05.
Calyxt (NASDAQ:CLXT) last posted its earnings results on Wednesday, November 14th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.50 million. Calyxt had a negative net margin of 6,256.67% and a negative return on equity of 33.08%. Equities analysts expect that Calyxt Inc will post -0.93 earnings per share for the current fiscal year.
In other news, insider Daniel F. Voytas sold 8,170 shares of Calyxt stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $13.00, for a total value of $106,210.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel F. Voytas sold 4,083 shares of Calyxt stock in a transaction that occurred on Tuesday, December 18th. The stock was sold at an average price of $13.00, for a total transaction of $53,079.00. The disclosure for this sale can be found here. Insiders have sold a total of 15,814 shares of company stock worth $198,086 in the last three months. Insiders own 2.80% of the company’s stock.
Several equities research analysts have recently issued reports on CLXT shares. Goldman Sachs Group upgraded shares of Calyxt from a “neutral” rating to a “buy” rating and raised their target price for the stock from $9.25 to $18.00 in a report on Sunday, December 16th. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 price objective on shares of Calyxt in a report on Thursday, November 15th. Zacks Investment Research lowered shares of Calyxt from a “buy” rating to a “sell” rating in a report on Wednesday, January 23rd. Finally, Citigroup decreased their price objective on shares of Calyxt from $19.00 to $13.00 and set a “neutral” rating for the company in a report on Monday, November 19th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $17.75.
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding CLXT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calyxt Inc (NASDAQ:CLXT).